PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
The Pharma Data
MAY 4, 2021
mg) in women with uterine fibroids. Relugolix combination tablet is currently under review by the FDA for the treatment of women with uterine fibroids, with a decision expected by the June 1, 2021 target action date. mg and norethindrone acetate 0.5 mg and norethindrone acetate 0.5 Amy Rose 212.733.7410. Source link.
40 
Let's personalize your content